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Abstract. The TP53-induced glycolysis and apoptosis regu-
lator (TIGAR) is the protein product of the p53 target gene, 
C12orf5. TIGAR blocks glycolysis and promotes cellular 
metabolism via the pentose phosphate pathway; it promotes 
the production of cellular nicotinamide adenine dinucleotide 
phosphate (NADPH), which leads to enhanced scavenging of 
intracellular reactive oxygen species, and inhibition of oxida-
tive stress-induced apoptosis in normal cells. Our previous 
study identified a novel nucleoside analog that inhibited 
cellular growth and induced apoptosis in nasopharyngeal 
carcinoma (NPC) cell lines via downregulation of TIGAR 
expression. Furthermore, the growth inhibitory effects of 
c-Met tyrosine kinase inhibitors were ameliorated by the 
overexpression of TIGAR in the NPC cell lines. These 
results indicate a significant role for TIGAR expression in the 
survival of NPCs. The present study aimed to further define 
the function of TIGAR expression in NPC cells. In total, 
36 formalin‑fixed, paraffin‑embedded NPC tissue samples 
were obtained for the immunohistochemical determination of 
TIGAR expression. The effects of TIGAR expression on cell 
proliferation, NADPH production and cellular invasiveness 
were also assessed in NPC cell lines. Overall, TIGAR was 
overexpressed in 27/36 (75%) of the NPC tissues compared 
with the adjacent non-cancer epithelial cells. Similarly, 
TIGAR overexpression was also observed in a panel of six 
NPC cell lines compared with normal NP460 hTert and Het1A 
cell lines. TIGAR overexpression led to increased cellular 
growth, NADPH production and invasiveness of the NPC cell 
lines, whereas a knockdown of TIGAR expression resulted 
in significant inhibition of cellular growth and invasiveness. 
The expression of the two mesenchymal markers, fibronectin 
and vimentin, was increased by TIGAR overexpression, but 
reduced following TIGAR-knockdown. The present study 
revealed that TIGAR overexpression led to increased cellular 
growth, NADPH production and invasiveness, and the mainte-
nance of a mesenchymal phenotype, in NPC tissues.
Introduction
The TP53-induced glycolysis and apoptosis regulator (TIGAR), 
which contains six coding exons and two p53 binding sites, 
is the protein product of a p53 target gene, C12orf5, located 
on chromosome 12p13-3 (1). Although p53 has already been 
established as a tumor suppressor protein, recent studies 
have demonstrated that by promoting cellular metabolism 
and blocking glycolysis via the TIGAR-mediated pentose 
phosphate pathway (PPP), p53 is also able to control cellular 
metabolism. In normal cells, this results in increased nicotin-
amide adenine dinucleotide phosphate (NADPH) production, 
enhanced scavenging of intracellular reactive oxygen species 
(ROS) and inhibition of oxidative stress-induced apoptosis. 
Therefore, the activation of TIGAR by p53 promotes an 
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antioxidant response that enables cells to survive during 
stressful conditions (2-4).
However, recent studies have revealed that deregulated 
TIGAR expression enhances the development of cancer by 
promoting the survival of cancer cells. In breast cancer, 
TIGAR expression was identified to protect the cells from 
undergoing apoptosis (5). In multiple myeloma cells, TIGAR 
was revealed to be necessary for the maintenance of redox 
homeostasis, whereas the downregulation of TIGAR resulted 
in myeloma cell death (6). In cases of hepatocellular carci-
noma, the suppression of TIGAR expression was identified 
to induce apoptosis and autophagy (7). Furthermore, in a 
mouse model of intestinal adenoma, TIGAR‑deficient mice 
exhibited reduced adenoma size and tumor burden compared 
with wild‑type mice. Overall, no significant difference was 
observed in the number of tumors, which suggested that 
TIGAR is primarily involved in tumor progression, rather 
than tumor initiation (4). In addition, the reduced tumor 
burden was correlated with an improved survival rate of 
the TIGAR‑deficient mice (4). This evidence suggested that 
TIGAR confers a protective function to cancer cells within 
multiple tissue types.
Nasopharyngeal carcinoma (NPC) is a metastatic and 
highly invasive Epstein-Barr virus (EBV)-associated cancer 
of the nasopharynx. The disease is particularly prevalent 
in China, with an annual incidence of up to 25 cases per 
100,000 individuals (8). At diagnosis, >60% of patients 
present with advanced stages of the disease, which due to 
distant recurrence or metastasis, are commonly unresponsive 
to treatment (9). Therefore, additional effective therapies are 
required for the treatment of NPC.
Our previous study revealed that a novel nucleoside analog 
inhibited cellular growth and induced apoptosis in NPC cell 
lines via downregulation of TIGAR expression (10). A further 
study demonstrated that the growth inhibitory effects of c-Met 
tyrosine kinase inhibitors were ameliorated by the overexpres-
sion of TIGAR in NPC cell lines (11). These results indicate 
a significant role for TIGAR expression in the survival of 
NPC cells. However, functional studies examining the role of 
TIGAR in NPC are lacking. The present study sought to inves-
tigate the expression pattern of TIGAR in NPC tumor tissues, 
and to analyze the consequences of TIGAR overexpression 
and knockdown on NPC cell growth and invasion.
Materials and methods
Antibodies. The antibodies used in the present study were rabbit 
anti-human TIGAR polyclonal antibody (cat no. ab37910, 
dilution, 1:8,000; Abcam, Cambridge, UK), rabbit anti-human 
fibronectin polyclonal antibody (cat no. sc-9068, dilution, 
1:2,000; Santa Cruz Biotechnology Inc., Dallas, TX, USA), 
mouse anti-pig vimentin monoclonal antibody (cat no. V6389, 
dilution, 1:1,000; Sigma-Aldrich, St. Louis, MO, USA), mouse 
anti-chicken actin monoclonal antibody (cat no. MAB1501, 
dilution, 1:100,000; Merck Millipore, Darmstadt, Germany), 
goat anti-mouse IgG polyclonal antibody HRP conjugate 
(cat no. 170-6516, dilution, 1:10,000; Bio-Rad Laboratories, 
Hercules, CA, USA) and goat anti-rabbit IgG polyclonal 
antibody HRP conjugate (cat no. 81-6120, dilution, 1:10,000; 
Thermo Fisher Scientific, Waltham, MA, USA).
Immunohis tochemist r y (IHC) s ta ining.  In tota l, 
36 formalin‑fixed, paraffin‑embedded specimens of undiffer-
entiated NPC, with adjacent normal epithelium, were retrieved 
from the archives of the Department of Pathology, Queen 
Elizabeth Hospital (Hong Kong, China).
The 4‑µm thick, formalin‑fixed, paraffin‑embedded serial 
tissue sections were cut, and antigen retrieval was performed at 
100˚C for 25 min using Bond Epitope Retrieval Solution 2 on 
the Bond-max automated immunostainer (Leica Microsystems, 
Wetzlar, Germany). The immunostaining was performed 
using a polymer detection system in the immunostainer with 
a rabbit polyclonal TIGAR antibody (1:500 dilution; Abcam), 
according to the manufacturer's instructions. Lymphoid cells 
were used as internal positive controls for TIGAR expres-
sion, and negative controls were constructed by replacing 
the antibody with Tris-buffered saline. The stained slides 
were analyzed in five fields using a light microscope (Leica 
DMLS; Leica Microsystems) at x400 magnification. The two 
independent observers were without knowledge of the clinical 
outcomes, and in the case of a disagreement, a consensus was 
reached following thorough discussion and slide examina-
tion using a multi-headed microscope (Leica DMLS; Leica 
Microsystems). In total, ~250 cells were counted in each field, 
and therefore at least 1,250 cells were counted for each tissue 
specimen. All the slides were scored semi-quantitatively and 
expressed as an IHC score by multiplying the percentage 
of positive cells by the staining intensity, as previously 
described (12). The staining intensity was scored as follows: 
0, negative; 1, weak; 2, moderate; 3, strong; and 4, very strong. 
The IHC score ranged from 0 to 400.
Cell lines. The HONE-1 NPC cell line was derived from patients 
with poorly-differentiated NPC (13,14). The HONE-1-EBV cell 
line was derived from the introduction of the EBV genome into 
the HONE-1 parental NPC cell line (15). The prototype latent 
membrane protein 1 (LMP1) was cloned from a B95.8 cell line. 
All the NPC cell lines were maintained in RPMI-1640 medium 
supplemented with 10% fetal bovine serum (Thermo Fisher 
Scientific), 100 U/ml penicillin, 100 µg/ml streptomycin and 
1 mm sodium pyruvate (Thermo Fisher Scientific). The cells 
were cultured at 37˚C with 5% CO2 in a cell culture incubator. 
The HONE-1-EBV cell line was maintained in a selection 
media containing 400 µg/ml G418 reagent (Thermo Fisher 
Scientific). The NP460 hTert cell line (obtained from Professor 
S.W. Tsao, Department of Anatomy, University of Hong Kong, 
Hong Kong, China) was maintained in a 1:1 dilution of Epilife 
medium and defined keratinocyte serum-free medium (KSFM; 
Thermo Fisher Scientific). The Het‑1A cells were obtained 
from the American Type Culture Collection (Manassas, 
VA, USA), and maintained in the KSFM supplemented with 
25 µg/ml bovine pituitary extract and 0.15 ng/ml epidermal 
growth factor (Thermo Fisher Scientific). The HONE-LMP1 
TIGAR-expressing cell line was established by the transient 
co-transfection of the TIGAR-overexpressing plasmid, or the 
respective control (OriGene, Rockville, MD, USA), into the 
parental HONE-1-LMP1 cell line using a pcDNA3.1(+) vector 
(Thermo Fisher Scientific). The cell line was then subjected to 
G418 selection for 3 months for single clone development, and 
maintained in a selection media containing 400 µg/ml G418 
(Thermo Fisher Scientific).
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Western blotting. The cell lysates were prepared as previously 
described (16). For the preparation of the NPC tumor biopsy 
lysates, six frozen endoscopy-guided biopsies, obtained from 
treatment-naïve NPC patients, were collected at the time of 
diagnosis. The patients consented to tissue collection for 
research purposes at the Tumor Bank, Department of Clinical 
Oncology, The Chinese University of Hong Kong (Hong Kong, 
China) according to the approved Ethics Approval of Research 
Protocol. The frozen tumor samples were homogenized using 
a pellet-pestle, disposable, cordless, hand-held homogenizer 
(Sigma-Aldrich) on ice in a western lysis buffer containing 
1.25 mm DTT, 5 mm phenylmethanesulfonylfluoride, 30 µg/ml 
leupeptin and 30 µg/ml aprotinin. In total, 50 µg protein was 
subjected to SDS-PAGE and immunoblotting, as previously 
described (17). Actin was used as the loading control.
Plasmid, siRNA and transfection. The pCMV-XL5 plasmid 
was used as the control vector for stable clone development in 
the transfection experiments. The HONE-1-LMP1 cells were 
plated at a density of 0.8x105 cells per well in a 10-cm2 plate. 
After 24 h, the cells were co-transfected using the pcDNA3.1(+) 
vector with 10 µg pCMV-XL5- or TIGAR-overexpressing 
plasmids (OriGene). Subsequent to 48 h of transfection, the 
cells were subjected to 400 µg/ml G418 selection for 3 months 
for clone development. The HONE-1-LMP1 cells were plated 
at a density of 1.2x105 cells per well in a 6-well plate. After 
24 h, the cells were transfected with 20 nM TIGAR or negative 
control siRNA (GE Healthcare Dharmacon, Inc., Lafayette, 
CO, USA), using Lipofectamine 2000 (Thermo Fisher 
Scientific). Subsequent to 48 h of transfection, the cells were 
harvested for western blotting to confirm TIGAR‑knockdown, 
and for the cell counting and Matrigel invasion assays.
Cell viability assay. The viable cell number of the stable 
clone- and siRNA-transfected cells was determined by a 
trypan blue exclusion assay. The cells were harvested and the 
cell number was determined by counting with 50% trypan 
blue (Thermo Fisher Scientific) on a hemocytometer. The 
experiments were performed at least three times, and triplicate 
wells were counted in each experiment.
Intracellular NADPH determination. The cellular NADPH 
production was determined using the EnzyChromTM 
NADP+/NADPH assay kit (Bioassay Systems, Hayward, CA, 
USA), as previously described (10). The protein concentration 
of the samples was determined using protein quantification, 
as previously described (17). The NADPH concentration was 
normalized to the total protein, and presented as µM/min/mg 
total protein. In total, at least three independent experiments 
were performed.
Matrigel invasion assay. Matrigel-coated Boyden inserts, 
with a pore size of 8 µm, were used for the invasion assay 
(BD Biosciences). The cells were seeded into the upper chamber 
at a density of 7x104 cells and maintained in serum-free medium. 
The cell-containing chamber was immersed in a lower chamber 
containing complete medium. The cells were incubated for 24 h 
at 37˚C in a 5% CO2 incubator. The non-invaded cells, which 
remained in the upper chamber, were removed with a cotton 
swab. The invaded cells were then stained with 1% toluidine 
blue O in 1% borax (Sigma-Aldrich) and counted under a 
microscope (magnification, x200). In total, 10 random fields 
were counted, and each experiment was performed in triplicate.
Statistical analysis. Statistical analyses were performed using 
PRISM4 software (GraphPad, San Diego, CA, USA). P-values 
were obtained using an unpaired t-test with Welch's correction. 
P<0.05 was considered to indicate a statistically significant 
difference.
Results
TIGAR is overexpressed in NPC tumors and cell lines. TIGAR 
protein expression was detected by western blotting in all the 
NPC tissue samples (Fig. 1A). In order to gain an understanding 
of the expression pattern of TIGAR in NPC tumors, IHC 
was used. Of the 36 NPC specimens, 27 (75%) demonstrated 
higher TIGAR IHC scores compared with the respective adja-
cent normal epithelial cells (ANECs) (Fig. 1B and C). With 
respect to the remaining nine NPC specimens, five (13.9%) 
Figure 1. TP53-induced glycolysis and apoptosis regulator (TIGAR) is 
overexpressed in nasopharyngeal carcinoma (NPC) tumors and cell lines. 
(A) Western blot analysis revealing the expression of TIGAR in six NPC 
tumor biopsies. (B) Immunohistochemistry (IHC) staining revealing TIGAR 
overexpression in NPC (left) and adjacent normal epithelial cells (ANECs; 
right) (magnification, x400). (C) IHC scores of TIGAR expression in tumor 
cells and ANECs, with a black horizontal line revealing the median score for 
each group. (D) TIGAR expression in multiple NPC cell lines with various 
differentiation statuses compared with the normal NP460 hTert nasopha-
ryngeal epithelial and Het1A esophageal epithelial cell lines. HONE-1, 
HONE-1-LMP1, HONE-1-EBV and CNE-2 were poorly-differentiated, HK-1 
was well-differentiated and C666-1 was undifferentiated. Actin served as the 
loading control. T, tumorous region; L, lymphocytes; NE, normal epithelium.
  A
  B
  C
  D
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demonstrated similar TIGAR IHC scores (±5) and 4 (11.1%) 
exhibited lower TIGAR IHC scores compared with the respec-
tive ANECs. In summary, the median TIGAR IHC scores of 
the tumor cells and the ANECs were 293.5 and 178, respec-
tively. Furthermore, the differences between the TIGAR IHC 
scores of the tumor and adjacent normal cells were statistically 
significant (P<0.0001; Mann‑Whitney U test).
Similar to the results obtained from the IHC, western 
blotting identified TIGAR overexpression across a panel of 
six NPC cell lines of varying differentiation statuses (HK-1 
was from differentiated from NPC; HONE-1, HONE-1-LMP1, 
HONE-1-EBV and CNE2 were from poorly-differentiated 
NPC; and C666-1 was from undifferentiated NPC) compared 
with the normal NP460 hTert nasopharyngeal cell line and 
the normal Het-1A esophageal epithelial cell line (Fig. 1D). 
TIGAR expression appeared to be increased by EBV infection 
or expression of the EBV LMP1 oncoprotein, as HONE-1-EBV 
and HONE-1-LMP1 expressed higher levels of TIGAR 
compared with the parental HONE-1 cells.
TIGAR promotes cell proliferation in NPC cells. The biological 
consequences of TIGAR upregulation in NPCs are unclear. 
Therefore, to investigate the functional role of TIGAR within 
NPC cells, endogenous TIGAR expression was knocked down 
in HONE-1-LMP1 NPC cells (Fig. 2A, upper panel). The 
results revealed that the knockdown of TIGAR expression led 
to significant growth inhibition of the HONE‑1‑LMP1 cell 
line (P=0.0125; unpaired t‑test; Fig. 2B). To further confirm 
the regulatory effect of TIGAR upon NPC cell proliferation, 
stable cells that overexpressed TIGAR were created with 
the HONE-1-LMP1 background (Fig. 2A, lower panel). As 
demonstrated in Fig. 2C, HONE-1-LMP1-TIGAR cells exhib-
ited a four-fold increase in cell growth compared with the 
HONE-1-LMP1-vector control cells (P<0.001; unpaired t-test). 
These findings indicate that TIGAR is capable of regulating 
NPC cell proliferation.
TIGAR expression promotes NADPH production in 
NPC cells. TIGAR has been reported to increase the produc-
tion of cellular NADPH, an antioxidant that is required for 
ROS scavenging and the inhibition of apoptosis through the 
PPP (2). In order to investigate whether TIGAR regulates 
NADPH production within NPC cells, TIGAR expression 
was knocked down in HONE-1-LMP1 cells by siRNA trans-
fection. The results in Fig. 2D reveal that the silencing of 
TIGAR in the HONE-1-LMP1 cells led to reduced amounts 
of cellular NADPH (P=0.0284; unpaired t-test). Furthermore, 
the overexpression of TIGAR in the HONE-1-LMP1-TIGAR 
stable cells led to a two-fold increase in NADPH production 
compared with the vector-stable cells (P=0.0069; unpaired 
t-test; Fig. 2E). These results indicate that TIGAR expression 
is capable of promoting NADPH production in NPC cells.
TIGAR promotes the invasiveness of NPC cells. In order to 
investigate whether TIGAR promotes the malignant proper-
ties of NPC cells, the effects of TIGAR overexpression on 
the invasiveness of the HONE-1-LMP1-TIGAR NPC cell 
line, compared with the vector stable cells, was examined. As 
revealed in Fig. 3A, TIGAR overexpression led to a five-fold 
increase in the number of NPC cells that invaded through the 
Matrigel (P<0.001; unpaired t-test). Furthermore, knockdown of 
TIGAR expression in HONE-1-LMP1 cells by RNAi reduced 
the number of cells that invaded through the Matrigel by ten-fold 
(P=0.035; unpaired t‑test; Fig. 3B). These findings demonstrate 
that TIGAR is involved in the promotion of NPC cell invasion.
TIGAR induces the expression of mesenchymal markers in 
NPC cells. During invasion and metastasis, tumor cells often 
Figure 2. TP53-induced glycolysis and apoptosis regulator (TIGAR) regulates nasopharyngeal carcinoma (NPC) cell growth and nicotinamide adenine 
dinucleotide phosphate (NADPH) production. (A) Western blot analysis revealing the knockdown (upper figure) and upregulation (lower figure) of TIGAR 
expression following transfection with TIGAR small interfering RNA and TIGAR-overexpressing plasmids, respectively. Knockdown of TIGAR (B) inhibited 
NPC cell growth and (C) depleted cellular NADPH production. The stable expression of TIGAR (D) promoted cellular proliferation and (E) increased NADPH 
production. Results are expressed as the mean ± standard error of the mean. *P<0.05, **P<0.01 and ***P<0.001 vs. the respective control group.
  A   B   C
  D   E
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undergo a process known as epithelial-mesenchymal transition 
(EMT) (18). In order to investigate whether TIGAR-induced 
NPC cells also undergo this process, the expression of several 
epithelial and mesenchymal markers was examined by western 
blotting. Fig. 4A reveals that the expression of the mesenchymal 
markers, fibronectin and vimentin, was upregulated in the 
HONE‑1‑LMP1‑TIGAR cells. This finding is consistent with the 
changes associated with a mesenchymal phenotype. Conversely, 
Fig. 4B demonstrates that the expression of fibronectin and 
vimentin was reduced upon TIGAR-knockdown. Together, 
these results indicate that TIGAR promotes the expression of 
mesenchymal markers in NPC cells, which may explain the 
increased invasiveness of TIGAR-expressing NPC cells.
Discussion
The present study demonstrated that TIGAR expression is 
upregulated in NPC tissues and cell lines. To the best of our 
knowledge, this study is the first to examine the expression of 
TIGAR in NPC tissues. The significant increase in TIGAR 
expression in the tumor cells compared with ANECs may indicate 
that TIGAR is involved in the development of NPC. The results 
correspond with those from recent studies in which TIGAR was 
revealed to be involved in the tumorigenesis of intestinal cancer 
and glioblastomas (4,19). This evidence suggests that TIGAR is a 
potential oncogene involved in various cancers. Further studies, 
which will include a larger cohort of specimens, are required to 
validate these findings and investigate the association between 
TIGAR expression and the clinical and histopathological 
features of NPC. Furthermore, functional tests, performed in a 
number of cell lines, are required in order to examine whether 
TIGAR is a potential therapeutic target for NPC.
In the HONE-1-LMP1 EBV-related NPC cell line, the 
overexpression of TIGAR promoted cellular NADPH produc-
tion, proliferation and invasion, and resulted in a concomitant 
upregulation of fibronectin and vimentin expression, which 
was indicative of a mesenchymal phenotype. Conversely, the 
knockdown of TIGAR by siRNA led to a reduction in cellular 
proliferation, invasiveness and NADPH production, and the 
reduced expression of fibronectin and vimentin. Together, these 
findings indicate that TIGAR promotes NPC cellular survival 
and invasiveness, and induces a mesenchymal phenotype.
TIGAR is the protein product of a p53 target gene, it exhibits 
fructose-2 and 6-bisphosphatase activity, and lowers the cellular 
levels of fructose-2,6-bisphosphate. This inhibits glycolysis and 
promotes the PPP, which increases the production of NADPH, 
and reduces the expression of glutathione (2). The synthesis 
of biomolecules and protection against oxidative stressors are 
processes necessary for cellular survival and that rely upon the 
antioxidant, NADPH (20,21). The results from the present study 
revealed that the overexpression of TIGAR upregulates cellular 
NADPH production. One of the major sources of oxidative 
stress within cells originates from the accumulation of ROS, 
which have the potential to lead to cell cycle arrest or cell death. 
In order to counteract the detrimental effects of ROS, cells 
increase the production of antioxidants, such as NADPH, which 
is a major source of the cellular reducing capability. In line with 
the pro‑survival role of NADPH, the present study identified 
that TIGAR overexpression increased NPC cell proliferation, 
while TIGAR-knockdown inhibited NPC cell proliferation. 
This demonstrated the specificity of the TIGAR-mediating 
growth effect in NPC cells. These results are consistent with 
those from a previous study, which identified that TIGAR 
prevented cell death via modulation of PPP activity (2). In the 
Figure 3. TP53‑induced glycolysis and apoptosis regulator (TIGAR) expression promotes cellular invasiveness. (A) A greater number of stable TIGAR-expressing 
nasopharyngeal carcinoma cells, compared with vector-transfected cells, invaded through the Matrigel layer. (B) A reduced number of TIGAR siRNA-transfected 
cells, compared with control siRNA‑transfected cells, invaded through the Matrigel layer. Cells invading through the Matrigel inserts were fixed, stained and counted 
under a microscope (magnification, x200). Results are expressed as the mean ± standard error of the mean. ***P<0.001 and *P=0.035 vs. the respective control group.
Figure 4. TP53-induced glycolysis and apoptosis regulator (TIGAR) induces 
the expression of mesenchymal markers. (A) TIGAR overexpression induced 
an increase in the expression levels of the mesenchymal markers fibronectin 
and vimentin, whereas (B) TIGAR-knockdown suppressed the expression of 
fibronectin and vimentin. Actin was used as the loading control.
  A   B
  A   B
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study, TIGAR reduced ROS levels and protected the cells from 
ROS-associated apoptosis, while TIGAR-knockdown sensitized 
the cells to p53-induced cell death. Consistent with the role of 
TIGAR in NPC cell survival, our previous studies revealed 
that TIGAR expression reversed the anti-proliferative effects of 
c-met tyrosine kinase inhibition on NPC cell growth (10,11). In 
summary, these findings provide significant evidence to support 
the role of TIGAR in NPC cell survival.
In the present study, TIGAR overexpression promoted 
NPC cellular invasion through the Matrigel, an effect that was 
ameliorated by the siRNA-mediated knockdown of TIGAR. 
This novel finding is significant in that distant metastases are 
the predominant cause of treatment failure in patients with 
NPC (8). The present study revealed that a downregulation 
of TIGAR expression inhibited NPC cell invasiveness. This 
finding may provide a novel therapeutic target for the treatment 
of patients with advanced stages of NPC, and one that may 
improve clinical prognoses. Furthermore, the regulation of 
TIGAR to prevent NPC cell invasion into surrounding tissues 
and prevent progression of the disease to more advanced 
stages may be investigated in future studies. At present, the 
precise mechanisms that underlie TIGAR-mediated NPC cell 
invasion are unclear. During tumor progression, carcinoma 
cells lose epithelial properties and undergo EMT to gain 
invasiveness. This process promotes tumor intravasation into 
lymph or blood vessels, and metastasis in distant organs (18). 
In cases of NPC, invasiveness and metastasis have been 
associated with EMT (22,23). In order to gain insight into the 
molecular changes associated with TIGAR-induced invasion, 
alterations in the expression of EMT markers were investi-
gated within the present study. The results demonstrated that 
the overexpression of TIGAR in the HONE-1-LMP1 NPC cell 
line upregulated the expression of the mesenchymal markers, 
fibronectin and vimentin, whereas the silencing of TIGAR led 
to downregulation. The role of TIGAR in the regulation of 
EMT is supported by a recent study, which revealed that the 
modulation of the p53/TIGAR pathway induced changes in 
the EMT status of a cervical carcinoma cell line (24). These 
findings suggested that the expression of TIGAR promoted 
NPC cellular invasion by initiating changes in the EMT 
phenotype.
In conclusion, the present study identified that TIGAR is 
overexpressed in NPC, where the protein is involved in the 
promotion of cellular proliferation, NADPH production and 
invasion, and in the expression of mesenchymal markers. 
Given that the involvement of TIGAR within these cellular 
processes may promote tumor progression, further investiga-
tions that examine how TIGAR supports NPC tumor growth, 
and the associated molecular pathways, are warranted.
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